Post-Operative Pain – Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 6 PAGES: 121

More Info
									Post-Operative Pain – Pipeline Review, H2 2011




            Post-Operative Pain – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1600IDB
                                                                                          Publication Date: December 2011




Post-Operative Pain – Pipeline Review, H2 2011                                            GMDHC1600IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Post-Operative Pain – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures ................................................................................................................................................................................ 9
Introduction....................................................................................................................................................................................... 10
    Global Markets Direct Report Coverage ...................................................................................................................................... 10
Post-Operative Pain Overview ......................................................................................................................................................... 11
Therapeutics Development............................................................................................................................................................... 12
    An Overview of Pipeline Products for Post-Operative Pain ......................................................................................................... 12
Post-Operative Pain Therapeutics under Development by Companies............................................................................................ 14
Post-Operative Pain Therapeutics under Investigation by Universities/Institutes ............................................................................. 16
Late Stage Products ......................................................................................................................................................................... 19
    Comparative Analysis .................................................................................................................................................................. 19
Mid Clinical Stage Products.............................................................................................................................................................. 20
    Comparative Analysis .................................................................................................................................................................. 20
Early Clinical Stage Products ........................................................................................................................................................... 21
    Comparative Analysis .................................................................................................................................................................. 21
Pre-Clinical Stage Products.............................................................................................................................................................. 22
    Comparative Analysis .................................................................................................................................................................. 22
Post-Operative Pain Therapeutics – Products under Development by Companies.......................................................................... 23
Post-Operative Pain Therapeutics – Products under Investigation by Universities/Institutes ........................................................... 24
Companies Involved in Post-Operative Pain Therapeutics Development ........................................................................................ 26
    DURECT Corporation .................................................................................................................................................................. 26
    A.P. Pharma, Inc. ........................................................................................................................................................................ 27
    Novartis AG ................................................................................................................................................................................. 28
    AcelRx Pharmaceuticals, Inc. ...................................................................................................................................................... 29
    Pfizer Inc...................................................................................................................................................................................... 30
    Bayer AG ..................................................................................................................................................................................... 31
    GW Pharmaceuticals plc ............................................................................................................................................................. 32
    NeurogesX, Inc. ........................................................................................................................................................................... 33
    PAION AG ................................................................................................................................................................................... 34
    BTG International Ltd .................................................................................................................................................................. 35
    Mundipharma International Limited ............................................................................................................................................. 36
    McGill University Health Center ................................................................................................................................................... 37
    SCOLR Pharma, Inc. ................................................................................................................................................................... 38
    Immupharma Plc ......................................................................................................................................................................... 39
    Neorphys ..................................................................................................................................................................................... 40
    Grunenthal GmbH ....................................................................................................................................................................... 41
    QRxPharma Limited .................................................................................................................................................................... 42
    Omeros Corporation .................................................................................................................................................................... 43
    Cara Therapeutics, Inc. ............................................................................................................................................................... 44
    Xenome Ltd. ................................................................................................................................................................................ 45
    KAI Pharmaceuticals Inc. ............................................................................................................................................................ 46



Post-Operative Pain – Pipeline Review, H2 2011                                                                                            GMDHC1600IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Post-Operative Pain – Pipeline Review, H2 2011



    Encore Therapeutics Inc.............................................................................................................................................................. 47
    SantoSolve AS ............................................................................................................................................................................ 48
    Endo Pharmaceuticals Inc. .......................................................................................................................................................... 49
    Gaia BioPharma Limited .............................................................................................................................................................. 50
    Qazvin University Of Medical Sciences ....................................................................................................................................... 51
Post-Operative Pain – Therapeutics Assessment ............................................................................................................................ 52
    Assessment by Monotherapy Products ....................................................................................................................................... 52
    Assessment by Combination Products ........................................................................................................................................ 53
    Assessment by Route of Administration ...................................................................................................................................... 54
    Assessment by Molecule Type .................................................................................................................................................... 57
Drug Profiles..................................................................................................................................................................................... 59
    Celebrex - Drug Profile ................................................................................................................................................................ 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    POSIDUR - Drug Profile .............................................................................................................................................................. 61
        Product Description................................................................................................................................................................. 61
        Mechanism of Action ............................................................................................................................................................... 61
        R&D Progress ......................................................................................................................................................................... 61
    Ibuprofen - Drug Profile ............................................................................................................................................................... 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    Morphine-6-glucuronide - Drug Profile ......................................................................................................................................... 64
        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    MoxDuo IR - Drug Profile ............................................................................................................................................................ 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    OMS103HP - Drug Profile ........................................................................................................................................................... 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    Celecoxib - Drug Profile ............................................................................................................................................................... 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    Etoricoxib - Drug Profile ............................................................................................................................................................... 70
        Product Description................................................................................................................................................................. 70
        Mechanism of Action ............................................................................................................................................................... 70
        R&D Progress ......................................................................................................................................................................... 70
    Oxycodone hydrochloride - Drug Profile ...................................................................................................................................... 71


Post-Operative Pain – Pipeline Review, H2 2011                                                                                          GMDHC1600IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Post-Operative Pain – Pipeline Review, H2 2011



        Product Description................................................................................................................................................................. 71
        Mechanism of Action ............................................................................................................................................................... 71
        R&D Progress ......................................................................................................................................................................... 71
    Eutectic Mixture - Drug Profile ..................................................................................................................................................... 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    Pregabalin - Drug Profile ............................................................................................................................................................. 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    Ketamine - Drug Profile ............................................................................................................................................................... 74
        Product Description................................................................................................................................................................. 74
        Mechanism of Action ............................................................................................................................................................... 74
        R&D Progress ......................................................................................................................................................................... 74
    Dexamethasone - Drug Profile .................................................................................................................................................... 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    Lignocaine - Drug Profile ............................................................................................................................................................. 76
        Product Description................................................................................................................................................................. 76
        Mechanism of Action ............................................................................................................................................................... 76
        R&D Progress ......................................................................................................................................................................... 76
    OMS302 - Drug Profile ................................................................................................................................................................ 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress ......................................................................................................................................................................... 77
    2PX - Drug Profile........................................................................................................................................................................ 78
        Product Description................................................................................................................................................................. 78
        Mechanism of Action ............................................................................................................................................................... 78
        R&D Progress ......................................................................................................................................................................... 78
    Lidocaine + Bupivacaine + Clonidine - Drug Profile..................................................................................................................... 80
        Product Description................................................................................................................................................................. 80
        Mechanism of Action ............................................................................................................................................................... 80
        R&D Progress ......................................................................................................................................................................... 80
    Dexmedetomidine - Drug Profile.................................................................................................................................................. 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 81
    Gabapentin - Drug Profile ............................................................................................................................................................ 82
        Product Description................................................................................................................................................................. 82
        Mechanism of Action ............................................................................................................................................................... 82
        R&D Progress ......................................................................................................................................................................... 82
    Gabapentin - Drug Profile ............................................................................................................................................................ 83


Post-Operative Pain – Pipeline Review, H2 2011                                                                                       GMDHC1600IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(4)
Post-Operative Pain – Pipeline Review, H2 2011



        Product Description................................................................................................................................................................. 83
        Mechanism of Action ............................................................................................................................................................... 83
        R&D Progress ......................................................................................................................................................................... 83
    Lidocaine - Drug Profile ............................................................................................................................................................... 84
        Product Description.............................................................................................................................................
								
To top